Summary of BeiGene Conference Call Company Overview - **Company**: BeiGene - **Date**: August 4, 2025 Key Industry Insights - BeiGene is positioned to achieve profitability due to the market expansion of products like Zanubrutinib, supported by significant R&D investments totaling hundreds of billions [2][8] - The company is advancing in the CDK inhibitor space, particularly focusing on selective CDK4 inhibitors to enhance safety, with preliminary efficacy data disclosed [2][5] - BeiGene is actively pursuing global multi-center clinical development to reduce costs and accelerate timelines, which enhances asset value and lowers risk [2][6] Core Points and Arguments - **R&D Investment**: BeiGene has invested hundreds of billions in R&D, utilizing both expensing and capitalization methods to support self-sustaining capabilities and global clinical development [2][8] - **CDK Inhibitors**: The company plans to initiate a Phase III study for second-line HR-positive breast cancer in Q4 2025, with ongoing exploration of CDK12 and CDK2 products [2][11] - **Clinical Development Strategy**: By independently conducting clinical trials, BeiGene has reduced costs and improved speed, allowing for quicker proof of concept (POC) results [2][6] - **Protag Platform**: The BDK protect product has entered Phase III trials, showing a progression-free survival (PFS) of 22.8 months, significantly outperforming similar drugs [2][12] - **ADC Developments**: BeiGene's B7H4 ADC has shown an overall response rate (ORR) of 48%, with plans to start Phase III trials in 2026 [2][17] - **Collaboration Opportunities**: As early pipelines yield POC results, BeiGene is expected to gain leverage in partnerships, particularly in the HR-positive breast cancer market [2][7] Additional Important Insights - **Safety Concerns**: BeiGene is addressing safety issues associated with CDK4/6 inhibitors, with initial results indicating a favorable safety profile compared to competitors [2][10] - **Future Plans**: The company anticipates 2025 to be a pivotal year for transitioning to profitability, with multiple early pipeline data readouts expected [2][23] - **Innovative Approaches**: BeiGene is exploring new drug mechanisms in the KRAS inhibitor space and has developed multi-specific antibody technologies [2][19][22] - **Market Potential**: The PRMT5 target for MTAP mutant tumors presents significant market potential, with plans for combination therapies to enhance efficacy [2][21] This summary encapsulates the critical insights and strategic directions of BeiGene as discussed in the conference call, highlighting its commitment to innovation and market expansion in the biopharmaceutical industry.

金融界8月4日消息，上证指数低开高走，中证香港100医药卫生指数 (H100医药，L11185)报1091.30点。 从中证香港100医药卫生指数持仓样本的行业来看，化学药占比54.55%、生物药品占比19.02%、制药与 生物科技服务占比15.26%、医疗商业与服务占比11.18%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当对应的母指数调整样本时， 行业指数样本将相应调整。当样本公司有特殊事件发生，导致其行业归属发生变更时，将对指数进行相 应调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照 计算与维护细则处理。 本文源自：金融界 作者：行情君 数据统计显示，中证香港100医药卫生指数近一个月上涨20.90%，近三个月上涨36.74%，年至今上涨 88.77%。 据了解，中证香港100行业指数系列将中证香港100指数样本按中证行业分类标准进行分类，再以各自行 业 ...

Core Insights - Since July, the A-share market has rebounded, leading to a continuous increase in financing balance, reaching 19,662.74 billion yuan as of August 1, with a net increase of 1,281.25 billion yuan in July, marking a new high in over 10 years [1][2] Financing Balance Overview - As of August 1, the A-share market's total margin balance is reported at 19,798.57 billion yuan, with the financing balance at 19,662.74 billion yuan, reflecting an increase of 1,281.25 billion yuan since July [2] - In the 24 trading days since July, financing balance increased on 21 days, accounting for nearly 90% of the time, with significant increases on July 21, 22, 28, and 29, each exceeding 150 billion yuan [3] Industry Performance - Among the 31 primary industries, 30 saw an increase in financing balance since July, with the pharmaceutical and biological industry leading with a net increase of 156.33 billion yuan, followed by electronics and power equipment [3] - The computer industry also reported a net increase of over 100 billion yuan, while only the oil and petrochemical industry experienced a net sell-off of 11.88 billion yuan [3] Stock Performance - The top ten stocks with the highest net buying amounts since July include Xinyi Technology (31.80 billion yuan), Northern Rare Earth (21.76 billion yuan), and Shenghong Technology (14.91 billion yuan), with most of these stocks showing significant price increases, particularly Feilihua, which rose nearly 60% [3] - Conversely, the top ten stocks with the highest net selling amounts include CITIC Securities (11.11 billion yuan) and Sunshine Power (7.67 billion yuan), with most of these stocks also experiencing price increases, notably Guangfa Securities, which rose over 15% [5] Margin Trading Overview - As of August 1, the margin trading balance reached 135.83 billion yuan, with an increase of 12.79 billion yuan since July, and a total of 28.72 billion shares available for margin trading [6] - The stocks with the highest margin trading balances include Kweichow Moutai (0.97 billion yuan), China Merchants Bank (0.68 billion yuan), and Ping An Insurance (0.68 billion yuan) [6]

Core Viewpoint - The article discusses the significant price disparity of prescription drugs in the U.S. compared to other developed countries, leading to new policies aimed at price control and the potential impact on multinational pharmaceutical companies and emerging markets [1][2]. Group 1: U.S. Drug Pricing Policies - U.S. prescription drug prices are 2-3 times higher than those in other developed countries, with some innovative drugs priced at 10 times higher than in China [1] - New policies require pharmaceutical companies to provide "most favored nation pricing" to U.S. Medicare, sign contracts for price locking, renegotiate overseas prices to "repatriate profits," and promote direct sales for price transparency [1][2] - The Pharmaceutical Research and Manufacturers of America (PhRMA) criticized these policies, claiming they would undermine U.S. innovation [1][2] Group 2: Multinational Pharmaceutical Companies' Strategies - Companies like Johnson & Johnson, Pfizer, and Merck are adopting multi-faceted strategies to balance profits and compliance, including adjusting global pricing strategies [3] - Some companies are lowering prices in the U.S. while increasing prices in other markets to maintain profit margins, with AstraZeneca already announcing price reductions for certain drugs in the U.S. [3][4] - To offset profit losses, companies may raise prices in emerging markets like China, where the annual treatment cost for PD-1 drugs is approximately 1.16 million yuan, ten times higher than in China [4] Group 3: Cost Optimization Strategies - Cost reduction is a core objective, leveraging China's low-cost advantages, where biopharmaceutical R&D costs are 1/5 to 1/10 of those in the U.S. [5] - Pfizer has signed over $1 billion in CDMO orders with Chinese companies to transfer some biopharmaceutical production to China, reducing production costs by 30% [5][6] - Companies are also transferring non-core technologies to China to avoid tariffs and lower costs, such as Pfizer's collaboration with Chinese firms to establish PD-1 production bases [6][7] Group 4: Legal and Policy Maneuvering - Industry associations and pharmaceutical companies are using legal and political avenues to resist new policies, with PhRMA planning to appeal to the WTO regarding the "most favored nation pricing" requirement [10] - They are lobbying Congress, arguing that foreign price controls could reduce U.S. R&D investment by $10 billion annually [10] Group 5: Opportunities and Challenges for Chinese Companies - Chinese companies are positioned to benefit from accelerated domestic substitution, with local biosimilars gaining price advantages [11] - CDMO businesses are expanding, with WuXi Biologics reporting a 144% year-on-year increase in CDMO revenue in the first half of 2025 [12] - Chinese pharmaceutical companies are also achieving breakthroughs in international markets through licensing agreements, with total upfront payments reaching $2.329 billion in the first half of 2025 [13] Group 6: Beneficiary Companies - Companies in the biosimilar sector, such as Innovent Biologics and Antengene, are expected to gain market share as multinational firms raise prices in China [16] - WuXi Biologics is recognized as a leading global CDMO, while other companies like Eastone and Hengrui are also expanding their CDMO projects [17] - Chinese firms that have established production facilities in India and Southeast Asia, like Huahai Pharmaceutical, are likely to benefit from reduced reliance on the U.S. market [19]

"创新药已从'主题投资'转向'产业趋势投资'。"某公募基金医药行业研究员表示，政策端，医保谈判简化、审评审 批加速等改革持续落地；技术端，ADC（抗体偶联药物）、双抗、细胞治疗等前沿领域进入成果收获期；资本 端，美联储加息周期接近尾声，全球生物医药投融资环境回暖，共同构成了本轮行情的底层逻辑。 从"至暗时刻"到"聚光灯下"，医药行业的反转行情印证了"创新驱动增长"的长期逻辑。（水手） 医药基金"王者归来"，单月最高涨34%。板块的强劲表现直接反映在基金净值上。Wind数据显示，截至7月31日， 全市场200余只医药主题基金（AC份额合并计算）中，超过80%年内实现正收益。其中，永赢医药健康A以34.2% 的单月涨幅领跑，华富健康文娱A、中银创新医疗A等7只基金涨幅超30%，形成明显的"赚钱效应"。 拉长时间维度看，医药基金的复苏势头更为显著。年内业绩排名前十的主动权益类基金中，中银创新医疗A、融 通健康产业A等9只产品均聚焦医药领域，与去年同期的"无人问津"形成鲜明对比。某头部基金公司市场部负责人 透露："近期渠道调研显示，投资者对医药基金的关注度提升至2021年以来的最高水平，新发基金中医疗健康主题 占比超 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期： 2025年8月1日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06160 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股 ...

市场全天震荡调整，三大指数小幅收跌。 盘面上，医药板块全线逆势走强，创新药概念延续强势，昂利康（002940）涨停；中药股展开补涨，维 康药业（300878）涨停；光伏概念反弹，捷佳伟创（300724）涨停；午后AI应用端活跃，智能体方向 领涨，鼎捷数智（300378）涨超10%；数据要素概念走强，深桑达A涨停。下跌方面，体育概念集体调 整，共创草坪（605099）跌停。 截至收盘，沪指跌0.37%，深成指跌0.17%，创业板指跌0.24%。市场热点快速轮动，个股涨多跌少，全 市场超3300家个股上涨。沪深两市全天成交额1.60万亿，较上个交易日缩量3377亿。 市场再现"技术性调整" 今日，A股市场震荡调整，三大指数均小幅下跌，量能较昨日大幅萎缩。 对于最近两日A股的杀跌，机构认为主要还是技术性调整。一方面，从市场结构而言存在涨幅快速积累 后的回调需求，指数摸高至3600点的过程中，不少板块站上阶段性高位，资金获利离场。另一方面，中 报季来临，进入8月中报期，市场将要开始验证上市公司业绩成色。 消息面上，快递行业近期催化颇多。一是国家邮政局召开快递企业座谈会，就依法依规治理行业"内卷 式"竞争，强化农村地区 ...

Core Insights - The Shanghai Composite Index decreased by 0.37%, while the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index fell by 1.74%, closing at 8507.96 points with a trading volume of 40.594 billion yuan [1] - Over the past month, the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index has increased by 17.84%, 24.27% over the last three months, and 34.48% year-to-date [1] Index Composition - The CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index is composed of 11 industry categories, reflecting the overall performance of different sectors within the index [1] - The top ten holdings in the index are: WuXi AppTec (10.42%), Hengrui Medicine (9.97%), BeiGene (9.63%), Innovent Biologics (6.64%), Mindray Medical (6.06%), WuXi Biologics (5.19%), CanSino Biologics (4.4%), China National Pharmaceutical Group (3.36%), CSPC Pharmaceutical Group (3.17%), and United Imaging Healthcare (2.85%) [1] Market Distribution - The market distribution of the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index shows that the Hong Kong Stock Exchange accounts for 37.87%, the Shanghai Stock Exchange for 33.61%, and the Shenzhen Stock Exchange for 28.52% [2] Sector Allocation - The sector allocation within the index includes: Chemical Drugs (36.20%), Pharmaceutical and Biotechnology Services (18.33%), Biopharmaceuticals (18.14%), Medical Devices (11.07%), Traditional Chinese Medicine (8.56%), and Medical Commerce and Services (7.70%) [2] Index Adjustment - The index samples are adjusted biannually, with adjustments occurring on the next trading day following the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] Fund Tracking - Public funds tracking the CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare Index include the China Merchants CSI Hong Kong-Shanghai-Shenzhen 500 Healthcare ETF [3]

Group 1 - The core viewpoint highlights the active trading and significant growth of the Science and Technology Innovation (Sci-Tech) Pharmaceutical ETF managed by Harvest, with a turnover rate of 21.72% and a transaction volume of 47.63 million yuan on July 31 [2] - Over the past week, the Sci-Tech Pharmaceutical ETF has seen an average daily transaction volume of 53.21 million yuan, ranking first among comparable funds [2] - The fund's scale increased by 16.78 million yuan in the past week, also leading among comparable funds, with a share increase of 12.50 million shares [2] Group 2 - The fund has attracted a total of 14.72 million yuan in inflows over the last five trading days [2] - As of July 31, the net value of the Sci-Tech Pharmaceutical ETF has risen by 48.77% over the past year, ranking 350 out of 2943 in the index stock fund category, placing it in the top 11.89% [2] - The fund's highest monthly return since inception was 23.29%, with the longest consecutive monthly gain being six months and a maximum increase of 41.76% [2] Group 3 - The top ten weighted stocks in the Shanghai Stock Exchange Sci-Tech Innovation Board Biopharmaceutical Index account for 49.14% of the index, with leading companies including United Imaging Healthcare and BeiGene [2] - The stock performance of the top ten companies shows mixed results, with some stocks experiencing slight declines while others have positive growth [4] Group 4 - The National Healthcare Security Administration has established a "new drug first launch price mechanism" to encourage drug research and innovation, marking a significant policy development [4] - The pharmaceutical and biotech sectors are expected to benefit from a high level of innovation and a potential revaluation of value stocks, with recommendations for companies in the Pharma and Biopharma/Biotech sectors [5] - The medical device industry is also anticipated to benefit from policy optimizations, with recent statements from relevant authorities supporting innovation and addressing issues of internal competition [5]

Group 1 - Company BeiGene (06160) announced that it will issue 741 ordinary shares due to the exercise of stock options by eligible participants (excluding company directors) from July 1, 2025, to July 31, 2025 [1]